AMGNAmgenSigning up patients
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 450 (planned)
- Started
- Jul 17, 2024
- Main results expected
- Sep 25, 2028
- Fully finished
- Apr 25, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Measured over: Up to Approximately 3 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06252649 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC